Trials / Conditions / Epstein-Barr Virus Associated Lymphoma
Epstein-Barr Virus Associated Lymphoma
3 registered clinical trials studyying Epstein-Barr Virus Associated Lymphoma — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Not Yet Recruiting | Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma NCT06788600 | Ruijin Hospital | — |
| Terminated | An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymp NCT05011058 | Viracta Therapeutics, Inc. | Phase 2 |
| Completed | Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancie NCT03397706 | Viracta Therapeutics, Inc. | Phase 1 / Phase 2 |